Status:
TERMINATED
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
Lead Sponsor:
Johns Hopkins University
Conditions:
CABG
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emer...
Detailed Description
After CABG surgery, a condition known as hyperglycemia or high blood sugar often occurs even in patients who have never been diagnosed with diabetes. This high blood sugar can lead to complications af...
Eligibility Criteria
Inclusion
- Males and Females age \> 18 years of age
- Able to consent
- Scheduled for non-emergent coronary artery bypass graft (CABG)
- Have an ejection fraction \< 35%
- Ischemic patients with Left Ventricular Dysfunction (LVD) who need a valve procedure with their CABG
Exclusion
- Emergency coronary artery bypass graft surgery
- Patients with an ejection fraction \> 35%
- Repeat or redo CABG patients
- Patients with a history of pancreatitis
- Pregnant or lactating females
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00966654
Start Date
September 1 2008
End Date
September 1 2012
Last Update
July 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205